Table of Contents
- Trial overview
- Who is being studied
- Treatment groups and study design
- Study phase and size
- What the trial measures
- What the data does not say
Trial overview
The available trial data describe one randomised Phase 2 study of AP31969 SULFATE for rhythm control in atrial fibrillation.[1] The study is interventional, which means researchers give a study treatment and compare outcomes between groups.[1]
The trial is authorised and is designed to assess the effect of AP31969 SULFATE on atrial fibrillation burden.[1] Atrial fibrillation is the condition being studied in this trial.[1]
Who is being studied
The target population is people with atrial fibrillation.[1] The source data do not give more detail about age limits, symptom requirements, or other entry rules.
Because this is a trial for rhythm control, the study is focused on people whose heart rhythm problem may be measured over time.[1] The trial data do not list any subgroup such as newly diagnosed patients or patients with a certain type of atrial fibrillation.
Treatment groups and study design
The study compares AP31969 SULFATE with placebo.[1] A placebo is a tablet that looks the same as the active study drug but does not contain AP31969 SULFATE.[1]
The source data list several oral AP31969 SULFATE tablet strengths: 200 mg, 400 mg, 700 mg, and 1000 mg.[1] The placebo tablets are described as visually identical to the active tablets, which helps keep the comparison fair.[1]
This design helps researchers compare outcomes between people receiving AP31969 SULFATE and people receiving placebo.[1] The trial brief summary says the goal is to assess the effect of AP31969 SULFATE on atrial fibrillation burden.[1]
Study phase and size
This is a Phase 2 trial.[1] Phase 2 studies usually look more closely at whether a treatment may work while continuing to gather safety information, but the source data only directly confirm the phase and study goal.
The planned enrollment is 200 people.[1] Enrollment means the number of participants the researchers plan to include in the study.
What the trial measures
The primary outcome is AF burden from week 2 to week 12.[1] Primary outcome means the main result the researchers want to measure.
AF burden means how much atrial fibrillation a person has during the study period.[1] By measuring this over time, the trial can show whether AP31969 SULFATE changes the amount of rhythm problem compared with placebo.[1]
What the data does not say
The source data do not list secondary outcomes, detailed eligibility rules, or follow-up beyond week 12.
The source data also do not provide results yet, so this trial description is about the study plan rather than the final findings.
